By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Generex Biotechnology Corporation 

33 Harbour Square
Suite 202
Toronto  Ontario  M5J 2G2  Canada
Phone: 416-364-2551 Fax: 416-364-9363


SEARCH JOBS


Industry
Biotechnology

Segment
Drug Delivery





Company News
Generex Biotechnology Corporation (GNBT) Announces Presentations Correlating Immunological Response With Reduced Recurrence In Phase 2 Study Of AE37 Breast Cancer Vaccine In Patients At The American College of Surgeons 10/27/2014 7:43:17 AM
Generex Biotechnology Corporation (GNBT) / Antigen Express, Inc. (GNBT) To Participate In 2014 Biotechnology Industry Organization (BIO)-Europe┬« Annual International Partnering Conference 10/23/2014 10:55:06 AM
Generex Biotechnology Corporation (GNBT) Announces Publication Of Ebola Vaccine White Paper By Antigen Express, Inc. (GNBT) 10/21/2014 9:30:53 AM
Generex Biotechnology Corporation (GNBT) Clarifies Utility Of Antigen Express Technology For Potential Ebola Vaccine 10/7/2014 9:43:37 AM
Generex Biotechnology Corporation (GNBT) Collaborates With University Health Network For Buccal Insulin Project 9/22/2014 8:12:49 AM
Generex Biotechnology Corporation (GNBT) / Antigen Express, Inc. (GNBT) To Participate In BioPharm America™ 2014 9/3/2014 9:09:38 AM
Generex Biotechnology Corporation (GNBT) Announces Publication Of AE37 Prostate Cancer Vaccine Study 8/6/2014 8:45:03 AM
Generex Biotechnology Corporation (GNBT) Announces Interview Of Dr. Eric Von Hofe, President Of Antigen Express, Inc. (GNBT), Following Recent Keynote Presentation 6/17/2014 10:27:43 AM
Generex Biotechnology Corporation (GNBT)/Antigen Express, Inc. (GNBT) Announce Interview Of MD Anderson Cancer Center's Dr. Elizabeth Mittendorf, Principal Investigator On Company's AE37 Phase IIb Breast Cancer Efficacy Trial 6/13/2014 12:45:03 PM
Generex Biotechnology Corporation (GNBT)/Antigen Express, Inc. (GNBT) Announce Interview Of MD Anderson Cancer Center's Dr. Elizabeth Mittendorf, Principal Investigator On Company's AE37 Phase IIb Breast Cancer Efficacy Trial 6/12/2014 8:21:57 AM
12345678910...
//-->